Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
about
The kinetics of blood brain barrier permeability and targeted doxorubicin delivery into brain induced by focused ultrasound.Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model.Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy.Doxorubicin, DNA torsion, and chromatin dynamics.Doxazolidine induction of apoptosis by a topoisomerase II independent mechanism.Green tea extracts attenuate doxorubicin-induced spermatogenic disorders in conjunction with higher telomerase activity in mice.Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma.Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in jurkat-T cells induced by doxorubicinAnthracycline cardiotoxicity: prevalence, pathogenesis and treatmentEnhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated miceClinical significance of ischemia-modified albumin in the diagnosis of doxorubicin-induced myocardial injury in breast cancer patients.Use of the comet assay technique for quick and reliable prediction of in vitro response to chemotherapeutics in breast and colon cancer.Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits.Phosphorylation of apoptosis repressor with caspase recruitment domain by protein kinase CK2 contributes to chemotherapy resistance by inhibiting doxorubicin induced apoptosis.Chemotherapy and cardiotoxicityDistinct roles for ROCK1 and ROCK2 in the regulation of cell detachment.Encapsulation of adriamycin in human erythrocytes.Immobilized doxorubicin increases the complement susceptibility of human melanoma cells by protecting complement component C3b against inactivation.Environmentally responsive peptides as anticancer drug carriers.Apoferritin as an ubiquitous nanocarrier with excellent shelf life.Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness.New functional degradable and bio-compatible nanoparticles based on poly(malic acid) derivatives for site-specific anti-cancer drug delivery.Interaction of adriamycin with DNA as studied by resonance Raman spectroscopy.Fabrication of elastin-like polypeptide nanoparticles for drug delivery by electrosprayingRapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography.Inhibition by adriamycin of calmodulin-sensitive and phospholipid-sensitive calcium-dependent phosphorylation of endogenous proteins from heart.Changes in ischemia-modified albumin in myocardial toxicity induced by anthracycline and docetaxel chemotherapy.Clinical evaluation of adriamycin, a new antitumour antibiotic.Fabrication of an electrochemical sensor for determination of doxorubicin in human plasma and its interaction with DNA.Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review.DNA-binding studies of valrubicin as a chemotherapy drug using spectroscopy and electrochemical techniques.Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.Effect of adriamycin on DNA, RNA and protein biosyntheses in mouse tissues, in connection with its cardiotoxicity.Enhanced Intestinal Permeation of Doxorubicin Using Chitosan Nanoparticles
P2860
Q28269056-F8F93A42-E4F4-4792-8A82-D587D181993FQ33845146-6E869479-36A8-4BC1-8CF9-458FF898C005Q33958482-957E1750-1C88-41AD-BDBC-A63DDE221287Q34039414-F0BD7682-50C8-4FE2-84AD-02F97B1FAF95Q34056786-EF521669-D969-468E-9C84-BB2394F1E49CQ34138132-1E253DCF-815D-451C-9E6D-C7575955364BQ34269228-45988332-EEF0-4454-94E7-D199401EE065Q34283227-E7551A44-A844-437C-93BC-8E35417005FAQ34639876-EC7DD7F2-68FC-4329-80D4-4E541D814562Q34766642-2672A86D-4909-44D0-93C3-03C3045197FAQ35041318-B7B74A41-6717-4BFD-B41C-5A97799E7227Q35317195-D68BEBF4-B72E-413C-9FDA-C81B96AEB229Q35875568-45CDD347-EAC2-42E5-9579-A40AD5005436Q36413878-08848D9C-2AE1-44B4-A0BC-341128C01E31Q37045339-33E9CF1A-B603-42D2-B66A-E6A914D12F78Q37073549-D2E3C935-7F83-4645-96FE-DDEEC28153E9Q37399860-E1CD5483-7FE7-4BCB-BDD7-099FA9895E79Q37409943-CD358634-F0A1-4845-891C-35838C61FCFAQ37560183-12A9A3ED-08C1-4216-85DC-315B2D18E32EQ38708389-B85824C0-82CA-48CA-8E00-CF21976D49BAQ39099572-CAB50979-D1CF-4AE0-A1CB-B69BADA556DAQ39546672-7EAD3C92-5FE0-4F97-88C2-5243C326D84DQ40464902-E3243952-E23E-478A-A475-E79435F9577CQ42018361-C0E900B1-7BED-4E11-841D-88045DB6039AQ42945549-32F7162B-D81C-48EB-B79B-AC39C66020C1Q46594915-0CB3B267-7E2C-4A86-A348-C01A47A111B4Q47969502-94B25DB6-DCA0-4FAE-AD28-0C9BFBC6B31DQ49203313-5139535D-27E7-451F-B427-369F348CF8ACQ49398803-129B0CCA-940D-4E1D-BF4B-228F0024DD51Q50047368-425F0F92-E52E-409B-A26A-F34DE2E4B0A1Q50142532-8CD4FDA3-294C-40AC-8577-55B77321A1CAQ50678211-E540617C-846F-48E0-A33C-854DA17D6230Q55331812-1C5F0868-8670-4047-8A29-69C3B5879B92Q57136235-30F0A530-FBF8-4C46-9E2E-979AD86A7A3E
P2860
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
description
1969 nî lūn-bûn
@nan
1969 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1969 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1969年の論文
@ja
1969年学术文章
@wuu
1969年学术文章
@zh-cn
1969年学术文章
@zh-hans
1969年学术文章
@zh-my
1969年学术文章
@zh-sg
1969年學術文章
@yue
name
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
@ast
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
@en
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
@nl
type
label
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
@ast
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
@en
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
@nl
prefLabel
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
@ast
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
@en
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
@nl
P2093
P1476
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
@en
P2093
A Di Marco
B Scarpinato
P577
1969-02-01T00:00:00Z